Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’ Tuesday 6th - Thursday 8th October 2020 (12.00-16.00 GMT daily) Programme Tuesday 6 October 12:00-12:15 Welcome Alan Hay, Francis Crick Institute, London, UK & Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA Introduction Jeremy Farrar, Wellcome Trust, London, UK Chairs TBC 12:15-12:40 COVID-19 Clinical Spectrum, Complications, and Coinfections Bin Cao, China-Japan Friendship Hospital, Beijing, China 12:40-13:00 COVID-19 Viral Replication Kinetics Malik Peiris, University of Hong Kong, HK SAR, China 13:00-13:20 COVID-19 Autopsy Findings Xiuwu Bian, China (TBC) 13:20-13:40 Immunopathogenesis of COVID-19 Peter Openshaw, Imperial College London, UK 13:40-14:00 Pathogenesis and Management of ARDS – Richard Wunderink, Northwestern University, Evanston, IL, USA 14:00-14:10 Comfort Break 14:10-15:10 Chairs TBC Oral Abstract Session 1 4 x 15 minute presentations (including Q&A) 15:10-15:20 Close of Day 1 Poster Viewing Page 1 of 3 Wednesday 7 October Chairs TBC 12:00-12:20 SARS-CoV-2 Antiviral Targets Mark Denison (accepted in principle) 12:20-12:40 Pre-clinical Models for Downselecting Candidates Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France 12:40-13:10 RECOVERY Trial and Strategies for Rapid Clinical Testing Peter Horby, Oxford, UK 13:10-13:30 Convalescent Plasma and Polyclonal Antibodies - Michael Joyner, Mayo Clinic, MN, USA 13:30-13:50 Monoclonal Antibodies Erica Saphire, La Jolla Institute for Immunology, CA, USA 13:50-14:00 Comfort Break 14:00-15:00 Chairs TBC Oral Abstract Session 2 4 x 15 minute presentations (including Q&A) 15:00-15:15 Close of Day 2 Poster Viewing Page 2 of 3 Thursday 8 October Chairs TBC 12:00-12:20 Lessons from MERS – Yaseen Arabi, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia 12:20-12:45 Solidarity Trial & Lessons Learned – Ana Maria Henao-Restrepo, WHO, Geneva, Switzerland (TBC) 12:45-14:15 Chairs TBC Clinical Trials Updates (15 minute presentations including Q&A) Remdesivir - Anu Osinusi, Gilead, Foster City, CA, USA EIDD-2801 - Wendy Painter, Ridgeback Biotherapeutics LP, Miami, FL, USA Favipirivir - Carol Epstein, Fujifilm Pharmaceuticals USA Inc., Cambridge, MA, USA JAK, IL-1, TNF inhibitors - John Beigel, NIAID, Bethesda, MD, USA Monoclonals for SARS and MERS – Sumathi Sivapalasingam, Regeneron, Tarrytown, NY, USA 14:15-14:25 Comfort Break Chairs TBC 14:25-14:45 Title TBC - Janet Woodcock, CDER, FDA, Washington DC, USA 14:45-15:00 Discussion on Clinical Trial Endpoints – moderated by Michael Ison, Northwestern University, Evanston, IL, USA 15:00-15:30 WHO Update on COVID-19 Clinical Management – Janet Diaz, WHO, Geneva, Switzerland 15:30-15:45 Summary and Close of Conference Page 3 of 3 .